XML 78 R71.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Additional Information (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 03, 2023
USD ($)
Item
Jan. 03, 2023
EUR (€)
Item
Jan. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jan. 03, 2023
EUR (€)
Revenue                  
Total revenue       $ 122   $ 455 $ 10,660    
Deferred revenue       212   212   $ 667  
License                  
Revenue                  
Total revenue             10,660    
Research and development services                  
Revenue                  
Total revenue       122   455      
License and Supply Agreement | Advanz Pharma                  
Revenue                  
Upfront payment received $ 10,700 € 10.0 $ 10,700            
Potential milestone payments to be received $ 142,200               € 134.0
Royalties as a percent of sales 20.00%               20.00%
Initial term 10 years 10 years              
Royalties as a percent of sales following initial term 10.00%               10.00%
Number of performance obligations | Item 3 3              
License and Supply Agreement | Advanz Pharma | License                  
Revenue                  
Amount of performance obligation               9,300  
Total revenue         $ 0   $ 10,700    
License and Supply Agreement | Advanz Pharma | Research and development services                  
Revenue                  
Amount of performance obligation               1,300  
Total revenue       100   500      
Deferred revenue       100   100   500  
License and Supply Agreement | Advanz Pharma | Manufacturing and supply material right                  
Revenue                  
Amount of performance obligation               100  
Deferred revenue       $ 100   $ 100   $ 100